Modality
Fusion Protein
MOA
DLL3 ADC
Target
USP1
Pathway
STING
CRCMDDPAH
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
Dec 2018
→ Oct 2031
NDA/BLACurrent
NCT07872588
1,312 pts·PAH
2019-01→2031-10·Not yet recruiting
NCT05927516
756 pts·MDD
2018-12→2027-04·Not yet recruiting
2,068 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-04-121.0y awayPh3 Readout· MDD
2031-10-075.5y awayPh3 Readout· PAH
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-04-12 · 1.0y away
MDD
Ph3 Readout
2031-10-07 · 5.5y away
PAH
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07872588 | NDA/BLA | PAH | Not yet recr... | 1312 | EASI-75 |
| NCT05927516 | NDA/BLA | MDD | Not yet recr... | 756 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 | |
| ETN-5063 | 89bio | Phase 1/2 | USP1 | |
| GLP-3342 | Galapagos | Phase 1/2 | PLK4 | |
| SOB-2861 | Sobi | Phase 2 | RET | |
| Pemilemzoparlimab | Astellas | Phase 1/2 | MALT1 |